Article
Hypermutation In Pancreatic Cancer.
Gastroenterology - 1 Jan 2017
Humphris Jeremy L, Patch Ann-Marie, Nones Katia, Bailey Peter J, Johns Amber L, McKay Skye, Chang David K, Miller David K, Pajic Marina, Kassahn Karin S, Quinn Michael C J, Bruxner Timothy J C, Christ Angelika N, Harliwong Ivon, Idrisoglu Senel, Manning Suzanne, Nourse Craig, Nourbakhsh Ehsan, Stone Andrew, Wilson Peter J, Anderson Matthew, Fink J Lynn, Holmes Oliver, Kazakoff Stephen, Leonard Conrad, Newell Felicity, Waddell Nick, Wood Scott, Mead Ronald S, Xu Qinying, Wu Jianmin, Pinese Mark, Cowley Mark J, Jones Marc D, Nagrial Adnan M, Chin Venessa T, Chantrill Lorraine A, Mawson Amanda, Chou Angela, Scarlett Christopher J, Pinho Andreia V, Rooman Ilse, Giry-Laterriere Marc, Samra Jaswinder S, Kench James G, Merrett Neil D, Toon Christopher W, Epari Krishna, Nguyen Nam Q, Barbour Andrew, Zeps Nikolajs, Jamieson Nigel B, McKay Colin J, Carter C Ross, Dickson Euan J, Graham Janet S, Duthie Fraser, Oien Karin, Hair Jane, Morton Jennifer P, Sansom Owen J, Grützmann Robert, Hruban Ralph H, Maitra Anirban, Iacobuzio-Donahue Christine A, Schulick Richard D, Wolfgang Christopher L, Morgan Richard A, Lawlor Rita T, Rusev Borislav, Corbo Vincenzo, Salvia Roberto, Cataldo Ivana, Tortora Giampaolo, Tempero Margaret A, Hofmann Oliver, Eshleman James R, Pilarsky Christian, Scarpa Aldo, Musgrove Elizabeth A, Gill Anthony J, Pearson John V, Grimmond Sean M, Waddell Nicola, Biankin Andrew V
Abstract excerpt
Pancreatic cancer is molecularly diverse, with few effective therapies. Increased mutation burden and defective DNA repair are associated with response to immune checkpoint inhibitors in several other cancer types. We interrogated 385 pancreatic cancer genomes to define hypermutation and its causes. Mutational signatures inferring defects in DNA repair were enriched in those with the highest mutation burdens....
Read the complete abstract on PubMed